PT - JOURNAL ARTICLE AU - Ighor Arantes AU - Felipe Gomes Naveca AU - Tiago Gräf AU - COVID-19 Fiocruz Genomic Surveillance Network AU - Fábio Miyajima AU - Helisson Faoro AU - Gabriel Luz Wallau AU - Edson Delatorre AU - Luciana Reis Appolinario AU - Elisa Cavalcante Pereira AU - Taina Moreira Martins Venas AU - Alice Sampaio Rocha AU - Renata Serrano Lopes AU - Marilda Mendonça Siqueira AU - Gonzalo Bello AU - Paola Cristina Resende TI - Emergence and Spread of the SARS-CoV-2 Variant of Concern Delta Across Different Brazilian Regions AID - 10.1101/2021.11.25.21266251 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.25.21266251 4099 - http://medrxiv.org/content/early/2021/11/28/2021.11.25.21266251.short 4100 - http://medrxiv.org/content/early/2021/11/28/2021.11.25.21266251.full AB - The SARS-CoV-2 Variant of Concern (VOC) Delta was first detected in India in October 2020. The first imported cases of the Delta variant in Brazil were identified in April 2021 in the Southern region, followed by more cases in different country regions during the following months. By early September 2021, Delta was already the dominant variant in the Southeastern (87%), Southern (73%), and Northeastern (52%) Brazilian regions. This work aimed to understand the spatiotemporal dissemination dynamics of Delta in Brazil. To this end, we employed a combination of Maximum Likelihood (ML) and Bayesian methods to reconstruct the evolutionary relationship of 2,264 of VOC Delta complete genomes (482 from this study) recovered across 21 out of 27 Brazilian federal units. Our phylogeographic analyses identified three major transmission clusters of Delta in Brazil. The clade BR-I (n = 1,560) arose in Rio de Janeiro in late April 2021 and was the major cluster behind the dissemination of the VOC Delta in the Southeastern, Northeastern, Northern, and Central-Western regions. The clade BR-II (n = 207) arose in the Paraná state in late April 2021 and aggregated the largest fraction of sampled genomes from the Southern region. Lastly, the clade BR-III emerged in the São Paulo state in early June 2021 and remained mostly restricted to this state. In the rapid turnover of viral variants characteristic of the SARS-CoV-2 pandemic, Brazilian regions seem to occupy different stages of an increasing prevalence of the VOC Delta in their epidemic profiles. This process demands continuous genomic and epidemiological surveillance toward identifying and mitigating new introductions, limiting their dissemination, and preventing the establishment of more significant outbreaks in a population already heavily affected by the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFinancial support was provided by Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM) (PCTI EmergeSaude/AM call 005/2020 and Rede Genomica de Vigilancia em Saude REGESAM); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (grant 402457/2020 0); CNPq/Ministerio da Ciencia, Tecnologia, Inovacoes e Comunicacoes/Ministerio da Saude (MS/FNDCT/SCTIE/Decit) (grant 403276/2020 9); Departamento da Ciencia e Tecnologia (DECIT), Ministerio da Saude; Inova Fiocruz/Fundacao Oswaldo Cruz (Grants VPPCB 007 FIO 18 2 30 and VPPCB 005 FIO 20 2 87), INCT FCx (465259/2014 6) and Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) (26/210.196/2020). This work was also supported by the Pan American Health Organization (PAHO), Brazil Country Office. F.G.N, G.L.W, G.B and M.M.S are supported by the CNPq through their productivity research fellowships (306146/2017 7, 303902/2019 1, 302317/2017 1 and 313403/2018 0, respectively). G.B. is also funded by FAPERJ (Grant number E 26/202.896/2018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Amazonas State University (CAAE: 25430719.6.0000.5016) and by the Ethics Committee of the FIOCRUZ (CAAE: 68118417.6.0000.5248).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomes were uploaded to the EpiCoV database in GISAID (https://www.gisaid.org/). https://www.gisaid.org/